Get all premium features to the best stock analysis tool

Regulatory Executive Brings More Than 15 Years of FDA, Medical Device, SaMD, and Digital Health Experience to Support AIML's Medical Device Strategy TORONTO, ON / ACCESS Newswire / September 1, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has appointed Dr. Mehmet A. Kosoglu, Ph.D.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / August 26, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement (the "Offering") pursuant to which the Company has issued an aggregate of 16,385,000 units ("Units") at a price of $0.05 per Unit to raise aggregate gross proceeds of $819,250. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant").

Pilot to Evaluate MaxYield™ and CardioYield™ in Real-World Mobile Holter Monitoring Workflow on Southern Vancouver Island TORONTO, ON / ACCESS Newswire / August 18, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has signed a non-binding commercial term sheet with Island Mobile Cardiology Testing ("Island Mobile"), a Victoria, British Columbia-based mobile cardiac testing provider, to conduct a pilot evaluation of NeuralCloud's MaxYield and CardioYield platforms. Island Mobile provides mobile cardiac testing services across Southern Vancouver Island, including 12-lead ECGs, 24-hour, 48-hour, and 3-day Holter monitoring, and ambulatory blood pressure monitoring.

TORONTO, ON / ACCESS Newswire / August 14, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it is proposing to complete a non-brokered private placement (the "Offering") pursuant to which the Company will issue up to 40,000,000 units ("Units") at a price of $0.05 per Unit to raise aggregate gross proceeds of up to $2,000,000. Each Unit will be comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant").

Quality Management System Certification Strengthens NeuralCloud's Regulatory Readiness for ECG Software-as-a-Medical-Device Platform TORONTO, ON / ACCESS Newswire / August 11, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has achieved ISO 13485:2016 certification under the Medical Device Single Audit Program ("MDSAP") for its quality management system. The certification, issued by TÜV USA, Inc., applies to NeuralCloud's quality management system for the design, development, production, and distribution of Software as a Medical Device ("SaMD") for ECG analysis, including advanced PQRST waveform delineation, interval computation, arrhythmia analytics, signal quality scoring, and artifact reporting.